Although direct clinical evidence of systemic NAD(P) depletion during GLP-1RA therapy is lacking, experimental and observational studies suggest that NAD turnover and micronutrient status can be altered in obesity and inflammatory states [83, 85], supporting the biological plausibility of substrate-sensitive vulnerability
It is evident that GLP-1s are becoming crucial for weight loss and can offer emerging health benefits to a wide range of individuals
Metabolic Health Benefits It improves overall metabolic rates and conditions, potentially lowering the risks associated with diabetes and heart disease
Injectable formulations may offer more consistent blood sugar control due to their superior bioavailability and steady drug levels throughout the week
Just discontinue the medication as soon as possible
Investigators reported a 38% higher risk of kidney cancer in GLP-1 users compared to non-users, noting that while the result was marginally nonsignificant, it remains concerning due to the widespread use of these drugs
